# Study of Dalantercept and Sorafenib in Patients With Advanced Hepatocellular Carcinoma

> **NCT02024087** · PHASE1,PHASE2 · COMPLETED · sponsor: **Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA** · enrollment: 21 (actual)

## Conditions studied

- Advanced Adult Hepatocellular Carcinoma

## Interventions

- **DRUG:** Dalantercept plus sorafenib

## Key facts

- **NCT ID:** NCT02024087
- **Lead sponsor:** Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-08-04
- **Primary completion:** 2017-07-05
- **Final completion:** 2017-09-22
- **Target enrollment:** 21 (ACTUAL)
- **Last updated:** 2022-09-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02024087

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02024087, "Study of Dalantercept and Sorafenib in Patients With Advanced Hepatocellular Carcinoma". Retrieved via AI Analytics 2026-06-15 from https://api.ai-analytics.org/clinical/NCT02024087. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*